481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors by Michael Manos, Patrick Ott, Anita Giobbie-Hurder, Osama Rahma, Nicole LeBoeuf, Kevin Tyan, Ai-Tram Bui, Isaac Klein, Leyre Zubiri, Kerry Reynolds, Shilpa Grover, Gerald Weinhouse

Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors by Ai-Tram N. Bui, Kevin Tyan, Anita Giobbie-Hurder, Isaac A. Klein, Michael P. Manos, Leyre Zubiri, Kerry Reynolds, Shilpa Grover, Gerald L. Weinhouse, Patrick A. Ott, Nicole R. LeBoeuf, Osama Rahma

Get full text

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid... by Ravit Geva, Jennifer Mataraza, Osama Rahma, Jason John Luke, Philippe L Bedard, Sarina A Piha-Paul, Angad Singh, Tira J Tan, Darren WT Lim, Cinta Hierro, Toshikiko Doi, Alexander Lesokhin, Javier Otero, Lisa Nardi, Alexandros Xyrafas, Xinhui Chen

Get full text

Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer by Arun Rajan, Renee N Donahue, Jeffrey Schlom, James L Gulley, Elizabeth Lamping, Osama Rahma, Houssein Abdul Sater, Jennifer L Marté, Beatriz Walter-Rodriguez, Yulia Vugmeyster, Yo-Ting Tsai, Shania Bailey, Wiem Lassoued, Richy Agajanian, Andrew Weisman, Rena Ito, Masashi Sato, Andreas Machl

Get full text

Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors by Harish Seethapathy, Sophia Zhao, Ian A. Strohbehn, Meghan Lee, Donald F. Chute, Halla Bates, Gabriel E. Molina, Leyre Zubiri, Shruti Gupta, Shveta Motwani, David E. Leaf, Ryan J. Sullivan, Osama Rahma, Kimberly G. Blumenthal, Alexandra-Chloe Villani, Kerry L. Reynolds, Meghan E. Sise

Get full text

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic... by Craig L Slingluff, Gina R Petroni, Todd Bauer, Nipun Merchant, Osama Rahma, Rawad Elias, Scott Rodig, Matthew H G Katz, Andressa Dias Costa, Brian M Wolpin, Stephanie K Dougan, Chee-Chee Stucky, Kathleen Pfaff, Gauri R Varadhachary, Victoire Cardot-Ruffino, Matthew J Reilley, Patrick Lenehan, Tanios S Bekaii-Saab, Jonathan Andrew Nowak

Get full text

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors by Mario Sznol, Michael Yellin, Tibor Keler, Jose Lutzky, Amy Weise, Margaret K Callahan, Osama Rahma, Rachel E Sanborn, Alexander Starodub, Deepa S Subramaniam, Antonio Jimeno, Tracey Rawls, David A Reardon, Daniel C Cho, Rhonda L Bitting, Michael J Pishvaian, Branimir I Sikic, Naiyer A Rizvi, Julie E Bauman, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Jeanny B Aragon-Ching, Thomas R Hawthorne

Get full text

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial by Xiaoyu Zhang, Anthony M Joshua, Sanjeev Kaul, Scott Antonia, Robert L Ferris, Roger B Cohen, Ezio Bonvini, Jan Baughman, Victoria Atkinson, Charu Aggarwal, Nicholas Vogelzang, Osama Rahma, Mahesh Seetharam, Yanyan Lou, Anthony Tolcher, Fernanda I Arnaldez, Amy Prawira, Ralph Hauke, Vinod Ganju, Andrew Weickhardt, Dan P Zandberg, Arash Rezazadeh Kalebasty, Alex A Adjei, Ariel Birnbaum, Rosetta Cavallo, Linda Peng, Paul A Moore, Stacie M Goldberg, Nehal J Lakhani

Get full text

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events by Namrata Singh, Maria E Suarez-Almazor, Iman Osman, Jeffrey Weber, Adi Diab, Petros Grivas, Noha Abdel-Wahab, Ala Abudayyeh, Huifang Lu, Osama Rahma, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Juhee Song, Jeffrey A Sparks, Sabina Sandigursky, Maya Dimitrova, May Daher, Maryam Buni, Kaysia Ludford, Faisal Fa'ak, Sarah H Chung, Uma Thanarajasingam, Adewunmi Falohun, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Emma J Montazari, Julia Chernis, Osama Abu-Shawer, Ashley M Zeman, Rafee Talukder, Jean H Tayar

Get full text

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

Get full text